Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment by Zhengtu Li et al.
RESEARCH ARTICLE Open Access
Efficacy of delayed treatment of China-
made Peramivir with repeated intravenous
injections in a mouse influenza model:
from clinical experience to basal
experiment
Zhengtu Li1†, Runfeng Li1†, Jing Li1†, Hui Xie1†, Yanbing Hao1, Qiuling Du1, Tingting Chen1, Yimin Li1,
Rongchang Chen1*, Zifeng Yang1,2* and Nanshan Zhong1,2
Abstract
Background: China-made Peramivir, an anti-influenza neuraminidase inhibitor drug, is manufactured and widely
used in China. Although effective if initiated within 48 h of the onset of symptoms, yet we observed that this drug
shows an inconclusive efficacy if treatment is delayed in clinical. Thus we evaluated the efficacy of delayed treatment
of China-made Peramivir in a mouse model.
Methods: The mouse model of influenza infection was made and Peramivir was administered intravenously for 5 days
following infection, and weight loss, lung index, viral shedding and survival rates were monitored.
Results: Peramivir (60 mg/kg · d, repeated intravenous injections, quaque die (QD) × 5 days) enhanced survival rate and
suppressed weight loss when treatment was initiated 24, 36, 48, or even 60 h post-infection (p.i.) (p < 0.01), compared
with the virus-untreated group, and efficacy was abolished at 72 h p.i.. However the efficacy of delayed treatment was
dose dependent, with the highest dose (90 mg/kg · d) even showing efficacy at 72 h p.i.. Furthermore, Peramivir
(60 mg/kg · d, repeated intravenous injections, QD × 5 days) also reduced the lung virus titer 24 and 36 h p.i. on
day 5, and even at 48 and 60 h p.i. on day 7 after infection, and the lung index was also improved. What is interesting
that the concentration of the drug was maintained in blood after infected.
Conclusions: Delayed treatment with China-made Peramivir can reduce the severity of influenza disease, accelerate
viral clearance and enhance the survival rate. This drug therefore shows good efficacy and is a promising candidate to
control the influenza epidemic in China.
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Background
Influenza virus poses a significant threat to human health,
leading to considerable morbidity and mortality worldwide.
Influenza pandemics, such as that caused by the influenza
A H1N1pdm2009 virus that began in Mexico in early 2009
and spread globally [1–3], result in significant rates of
hospitalization and death [4, 5]. Epidemic spread within a
population can also lead to severe illness and death [6].
High rates of influenza infection are reported in China,
particularly in the south of the country. The Centers for
Disease Control (CDC) of China have reported data indi-
cating two seasonal peaks in the number of cases of influ-
enza infection in southern China each year, including
human infections with highly pathogenic avian influenza
viruses, such as H7N9/H10N8/H5N6 [7–9]. Therefore,
more anti-viral drugs are needed in China to help combat
this serious human infection.
The anti-influenza neuraminidase inhibitor drugs (for
example, Oseltamivir, Zanamivir and Peramivir) are
commonly used to prevent and treat influenza infection
[10]. The M2 ion channel blockers (for example, aman-
tadine and rimantadine) are less effective because of
high drug resistance and adverse side effects [11–14]. Of
these neuraminidase inhibitors, only Oseltamivir and
Peramivir are manufactured in China and therefore most
widely used in this country. Previous clinical trials indi-
cated that treatment with neuraminidase inhibitors
needed to be initiated within 48 h of the onset of symp-
toms [15–19]; however, owing to the delayed diagnosis
of pathogens, anti-viral treatment in China was usually
initiated after this time period, for example H7N9
patients were treated with neuraminidase inhibitors be-
yond 48 h after the onset of illness [20]. Furthermore,
China-made Peramivir was also used to treat H7N9
patients in Guangzhou who had failed to respond to
Oseltamivir, but this drug showed variable delayed treat-
ment efficacy [21]. Therefore, research is required into
the efficacy of delayed treatment with neuraminidase in-
hibitors, particularly China-made Peramivir, which is ap-
proved as an intravenous neuraminidase inhibitor [22]
and showed a degree of efficacy clinically in patients in
Guangzhou [21].
To investigate the efficacy of delayed treatment of
Peramivir, manufactured in China, we employed a mouse
model of influenza infection. Peramivir was administered
intravenously, started at 24, 36, 48, 60 or 72 h p.i., for
5 days following infection, and viral shedding and survival




Viruses used in this study included Influenza A
H1N1pdm2009 (A/GZ/GIRD07/09, H1N1), isolated
from fever patients in Guangzhou city between June and
October 2009 and identified by genome sequencing, and
Influenza B (B/Guangzhou/GIRD08/09), purchased from
the CDC. These viruses were bred in the allantoic cav-
ity of 9-d-old embryonated chicken eggs for 48 h at
35 °C, then 12 h at 4 °C, following which the harvested
viruses were preserved at −80 °C prior to use. From
these viruses, mouse lung-adapted variants were gener-
ated by repeated infection of mice. The 50 % lethal dose
(LD50) of mouse, a simple method of estimating 50 %
endpoints, was determined.
Animal experiment design
BALB/C mice (6–8 weeks old) were purchased from
Guangdong Medical Laboratory Animal Center
(Guangzhou, China). The mice were housed in
specific-pathogen-free facilities, bred, and genotyped
according to the vendor’s protocols.
For lung index and lung virus titer determination, mice
were treated with saline (50 μL) or virus (H1N1pdm2009:
3 LD50; influenza B: 10 LD50; in 50 μL saline) by intranasal
inhalation with ether anesthesia. The experimental group
were treated with Oseltamivir (purchased from EP com-
pany, lot 005171; dissolved in saline) via the oral route, or
Peramivir (a gift from Hunan Nonferrous Kay Platinum
Biological Pharmaceutical Co., LTD, China; lot 20140806;
dissolved in saline) via tail intravenous injection. The nor-
mal control group and virus control group mice were
treated with saline via oral administration. The drugs were
administered for 5 days starting at 24, 36, 48, 60 or 72 h
after infection, and mice were euthanized 5 or 7 d after
influenza virus infection.
For the death protection experiments, mice were chal-
lenged with viruses, treated with Oseltamivir or Peramivir
for 5 days, then observed over 15 days. Mice that died
during drug treatment were treated as abnormal deaths.
Finally, survival rates and average survival times were
calculated.
For pharmacokinetic evaluation, mice were infected
with H1N1pdm2009 virus, then the normal control
group and the virus group were treated with Peramivir
(60 mg/kg) after 48 h infection. Blood was collected
from the suborbital vein at 0.5, 5, 10, 15, 20, 30, 40, 60
and 90 min after treatment. About 500 μL of blood per
sample was collected into heparinized tubes and then
immediately centrifuged at 4000 × g for 10 min. The
plasma obtained was stored at −20C until analysis.
Lung index determination and lung virus titer determination
Mice were euthanized at 5 or 7 d after virus challenge.
Lung tissues were harvested and weighed. The lung
index was expressed as the ratio of mean lung weight to
mean body weight (lung index = lung weight/body
weight × 100). The lung samples were homogenized in
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1 mL of PBS, centrifuged at 10,000 g/min for 10 min,
then the supernatant was collected. Virus titer was
determined by the cytopathic effect method [23].
Drug pharmacokinetic determination
Standard and sample preparation
Primary working solution of Peramivir was prepared by
dissolving an accurately weighed amount (to 0.01 mg
precision) in acetonitrile: water (1:1) to yield 1 mg/mL.
For the assay of Peramivir in plasma samples, working
standard solutions at 0.1, 0.25, 2.5, 5, 10, 20, 30, 60 and
20 μg/mL concentrations of Peramivir in acetonitrile:
water (1:1) were prepared. Calibration standards of
Peramivir were prepared by spiking 100 μL of fresh
blank lean mice plasma with 10 μL of a standard Pera-
mivir working solution, producing calibration samples
with plasma concentrations of 0, 50, 100, 500, 1000,
2000, 4000, 6000, 12000 and 40000 ng/mL. The internal
standard (IS) stock solution was prepared at 1 mg/mL in
acetonitrile: water (1:1) in 1 mg/mL and was further di-
luted in acetonitrile to yield a working standard solution
of 400 ng/mL. All solutions were stored at 4 °C and
brought to room temperature before use.
To 100 μL of sample or blank plasma, a 10-μL aliquot
of the IS solution (final concentration, 400 ng/mL),
10 μL of acetonitrile: water (1:1) or standard working
solution was added. The mixture was extracted with
800 μL of ethyl acetate by shaking for 15 min. After cen-
trifugation at 14,000 × g for 10 min, the upper organic
layer was separated and evaporated at 45 °C under a
stream of nitrogen in a Turbo Vap evaporator (Zymark,
Hopkinton, MA, USA). The residue was reconstituted in
100 μL of the mobile phase, and then mixed by vortex
ING. A 20-μL aliquot of the resulting solution was
injected into the LC-MS/MS system for analysis.
HPLC-MS/MS conditions
The LC-ESI-MS/MS system consisted of a nanospace
HPLC system (NANOSPACE 1312, Japan) coupled to a
Q Trap™ 4000 hybrid triple quadruple linear ion trap
mass spectrometer (Applied Biosystems/MDS Sciex,
Concord, Ontario, Canada). Data were processed using
the Analyst™ 1.5 software package (Applied Biosystems,
MA, USA). Chromatographic separation was performed
on a Luna C18 column (2.1 × 50 mm, 1.7 μm; CA, USA)
at ambient temperature. The flow rate was 0.4 mL/min
and the injection volume was 10 μL.
For LC-ESI-MS/MS detection, mobile phase A com-
prised water with 0.1 % formic acid and phase B com-
prised acetonitrile with 0.1 % formic acid. In the LC
gradient profile, mobile phase B comprised 10 % (v/v) at
the start, increased linearly to 100 % from 0.5 to 2.2 min
and then returned to 10 % at 3.2 min, with a total run
time of 4.0 min.
The mass spectrometer was operated using an ESI
source in the positive ion detection mode for Peramivir
and Oseltamivir (IS) determination. Acquisition was per-
formed in the MRM mode using m/z values of 329.2/270.3
and 313.1/208.2 for Peramivir and IS, respectively. The op-
timized instrument parameters for monitoring the analytes
by MS were as follows: source temperature, 650 °C; curtain
gas, 30 psi; nebulizing gas, 80 psi; turbo ion spray gas,
70 psi; collision gas, medium; dwell time 100 ms.
Statistical analysis
Data are presented as the mean ± SD. All data were ana-
lyzed using GraphPad and SPSS 17.0 software. Weight
loss data were checked by repeated measurements and a
mixed model multivariate analysis of variance. Statistics
were analyzed with ANOVA or the two-tailed Student’s
t-test. The probability of mouse survival was estimated
by the Kaplan-Meier method and further analyzed by
log-rank pairwise tests over strata. The pharmacokinetic
profile and parameters of Peramivir were analyzed using
DAS 2.0 pharmacokinetic software. Statistical signifi-
cance was set as p < 0.05; p < 0.01 and p < 0.001 were
considered as more significant differences.
Results
Clinical anti-viral treatment features of H7N9 patients in
Guangdong province, China
In previous clinical trials, neuraminidase inhibitors only
showed anti-influenza efficacy if administered within
48 h of the onset of symptoms [15–19]. However, we
found a good treatment efficacy of neuraminidase in-
hibitors beyond 48 h, even up to 22 days after the onset
of symptoms (Table 1). In our observations, H7N9 pa-
tients were usually treated late with anti-viral drugs,
with the earliest treatment time being 7 days after the
onset of illness among our patients (Table 1). Further-
more, Peramivir, manufactured in China, showed a
Table 1 Clinical anti-viral treatment features of H7N9 patients in
Guangdong province, China
Patient Time (days) after onset of
symptoms when anti-viral
drugs were administered
Anti-viral drug used Clinical
outcome
1 22 Oseltamivir Survival
2 8
3 8
4 7 Oseltamivir, China-made
Peramivir
Survival
5 13 Oseltamivir, Zanamivir,
China-made Peramivir
Death
6 9 Oseltamivir, Zanamivir Survival
7 11
*Some of these data were published by our research team, Zifeng Yang et
al. [21]
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degree of treatment efficacy (Table 1). The patient who
died had a history of lung cancer.
Delayed treatment with China-made Peramivir enhanced
survival, suppressed weight loss and reduced lung virus
titer
In the mouse influenza model, viral infection leads to
high mortality and weight loss [24]. Therefore, the effi-
cacy of delayed treatment of Peramivir was first evalu-
ated with the survival rate, mean days to death and
weight loss. The mouse model was set up as described
in the Materials and Methods. Peramivir was adminis-
tered at 60 mg/kg · d QD for 5 days and survival rates of
100, 80, 70 and 80 % were observed 24, 36, 48 and 60 h
post-infection (p.i.), respectively (p < 0.01, compared
with 10 % of the virus group), compared with 77.8, 55.6,
30 and 77.8 % survival rates in the Oseltamivir group
under the same conditions (Fig. 1a). However, there was
no efficacy for delayed treatment at 72 h p.i. for the two
groups, and the mean number of days to death was only
extended in the 24 h p.i. (>15 days) group compared
with 8.33 ± 2.29 days in the virus group. Furthermore,
the virus-infected mice exhibited a tendency toward
weight loss from day 3 p.i., peaking on day 9. However,
weight loss was suppressed in mice treated with Peramivir.
At its peak (day 9), there was a clear difference (about
9 %) in weight loss suppression in the post-24-h treatment
group only compared with the virus group. Meanwhile, on
the last day of monitoring (day 15), there was significant
weight loss suppression post-24 to post-72-h p.i. (p < 0.05,
compared with the virus group). These effects were more
marked in the Peramivir group compared with the
Oseltamivir group (Fig. 1b).
The lung virus titer was also detected in each of the
treatment groups. On day 5 p.i., the Peramivir treatment
reduced lung virus titers only when treatment was initi-
ated post 24 and 36 h (p < 0.05, compared with the virus
group), which was an improved outcome compared with
Oseltamivir treatment. However, on day 7, the lung virus
titer was reduced by 24, 36 and 60 h (p < 0.05, compared
with the virus group) for the Peramivir and Oseltamivir
groups (Fig. 1c). Furthermore, the lung index showed an
improvement at 24 to 72 h p.i. (p < 0.05, compared with
the virus group) (Fig. 1d), indicating the increased treat-
ment efficacy of Peramivir compared with Oseltamivir
treatment. When Peramivir (40 mg/kg · d, QD for 5 days)
was administered to influenza B virus-infected mice, the
lung index was improved in the prevention and treatment
model, even showing improved efficacy at 72 h p.i. on day
7 (p < 0.01, compared with the virus group) (Fig. 1e).
The efficacy of delayed treatment with Peramivir was
dose dependent. At 40 mg/kg · d, the survival rate was only
enhanced at 24 h p.i. (p < 0.05, compared with the virus
group), and efficacy was observed at 48 h p.i. at 60 mg/kg ·
d (p < 0.05, compared with the virus group). Furthermore,
the efficacy of delayed treatment of Peramivir was even
observed at 72 h p.i. (p < 0.05, compared with the virus
group) at 90 mg/kg · d (Fig. 1f).
Concentration of China-made Peramivir can be maintained
after virus infection in the mouse influenza A
H1N1pdm2009 model
A rough quantitation of blood Peramivir showed a lower
concentration than that reported from a phase I clinical
trial [25]. Furthermore, the previous study about the
blood drug concentration of Peramivir was showed on
the normal animal model [26]. We therefore investigated
whether influenza virus infection affects the pharmacokin-
etics of Peramivir. As results shown, there were no signifi-
cant differences in the concentration of Peramivir in the
blood of influenza A H1N1pdm2009 virus-infected mice
compared with normal mice, but slight increases were
generally observed in the influenza A H1N1pdm2009
virus-infected mice (Fig. 2). Furthermore, the simulated
pharmacokinetic parameters of Peramivir also showed no
significant differences between influenza virus-infected
mice and normal mice and; however, the mean retention
time (MRT) was extended in the influenza virus-infected
mice (Table 2).
Discussion
The present study provides evidence demonstrating that
delayed treatment of China-made Peramivir can enhance
the survival rate, inhibit virus replication in the lung,
decrease the severity of viral lung lesions and remain at
a stable concentration in the blood in the influenza virus
infection mouse model.
Peramivir is a potent neuraminidase inhibitor of influ-
enza that has been approved for intravenous use [27].
The in vitro activity of Peramivir has been shown to be
comparable to, or better than, Oseltamivir carboxylate
and Zanamivir [24]. Peramivir is unlike Oseltamivir
(oral) and Zanamivir (inhalation) that are only suitable
for treating cooperating patients, as it is suitable for the
treatment of severely ill patients who cannot accept oral
or inhaled treatments. For these reasons Peramivir was
used to treat H7N9 patients (Table 1), but its clinical ef-
ficacy is yet to be confirmed. In this study, we observed
that Peramivir treatment was usually delayed in patients
owing to late diagnosis (Table 1). It was therefore im-
portant to determine the efficacy of delayed treatment of
Peramivir, which we investigated in the mice model.
Peramivir (60 mg/kg · d, intravenous injection, QD for
5 days) enhanced the survival rate of mice even when
initiated 60 h p.i., compared with Oseltamivir (60 mg/
kg · d, oral, QD for 5 days) (Fig. 1a). A previous report
showed that a single intramuscular dose of Peramivir
(10 mg/kg) administered at 24 or 48 h p.i. prevented
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death in a similar manner to Oseltamivir and Zanamivir
treatment [24]. Another report showed that Peramivir,
given as late as 60 h after infection, was able to prevent
death in mice [28], similar to our findings, except that
these studies administered a single intramuscular dose
whereas we used repeated intravenous injections.
A clinical study found that repeated intravenous injec-
tions of Peramivir for 5 days conferred beneficial effects
Fig. 1 Delayed treatment of China-made Peramivir enhanced survival, suppressed weight loss and reduced lung virus titer. Mice were administered
virus (H1N1pdm2009: 3 LD50; in 50 μL saline) via inhalation to induce acute lung inflammation, and were then treated with Peramivir (60 mg/kg · d,
intravenous injection, QD × 5 days) and Oseltamivir (60 mg/kg · d, oral, QD × 5 days). Survival rate (a) and body weight (b) were determined daily for
15 d. Viral titers in the lungs (c) on days 5 and 7 were determined by the cytopathic effect method and the plaque assay. d Lung index of each group
on days 5 and 7. The index was determined as the lung weight/final body weight (LW/BW). e Mice were administered virus (influenza B
virus: 10 LD50; in 50 μL saline) via inhalation, and were then treated with Peramivir (40 mg/kg · d, intravenous injection, QD × 5 days). Lung
index of each group on days 5 and 7 were calculated. f Mice were treated with different doses of Peramivir (40, 60 and 90 mg/kg · d), and the survival
rate was determined daily for 15 d. Values are shown as mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 Peramivir group versus virus control group;
#p < 0.05, ##p < 0.01 and ###p < 0.001 Ositamivir group versus virus control group. Statistical analyses were performed consecutively with ANOVA or
the two-tailed Student’s t-test
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in influenza virus-infected patients at high risk of com-
plications, and no major safety issues were identified
[29]. In addition, another study reported no obvious
signs of drug-related toxicity in mice after repeated
intravenous injections of Peramivir at a dose of 40 mg/
kg · d for 20 days [30]. They also found that repeated
administration of Peramivir (40 mg/kg · d, intravenous
injection, QD × 20 days) starting at 24, 48 or 72 h p.i. re-
sulted in increased survival rates and reduced viral titers
in the lungs. These findings demonstrated higher efficacy
for delayed treatment than with Peramivir, potentially due
to prolonged usage. In our study, we also found that the
efficacy of delayed treatment of Peramivir was dose
dependent (Fig. 1f). In the mouse model, Peramivir treat-
ment showed no signs of toxicity or side effects at doses
as high as 3000 mg/kg · d administered as a single dose or
at doses of 1000 mg/kg · d administered for 5 days [31], in-
dicating that prolonged treatment and higher doses of
Peramivir may enhance the efficacy of delayed treatment.
Clinically, we found that Peramivir even administered on
day 7 p.i. also presented some treatment efficacy (Table 1),
potentially indicating some differences between humans
and mice and demonstrating the need for more clinical
trials to evaluate the real efficacy of delayed treatment of
Peramivir.
A single intramuscular injection of Peramivir (10 mg/
kg) significantly reduces weight loss and mortality in
mice infected with influenza A/H1N1, while Oseltamivir
demonstrates no efficacy by the same treatment regi-
men. This has been suggested to be due to tight binding
of Peramivir to the N1 neuraminidase enzymes [24]. In
our study, we also observed the efficacy of delayed treat-
ment of Peramivir combined with reduced lung virus
titer (Fig. 1c/d), which may be potentially attributable to
the tight binding of neuraminidase enzymes reducing
virus replication. The drug concentration in blood is also
important for drug efficacy. The lack of significant clin-
ical effects may be due to the relatively low blood levels
that were obtained following oral administration, indi-
cating the low oral bioavailability of Peramivir (≤3 %).
We demonstrated that the concentration of Peramivir in
blood can be maintained after virus infection (Fig. 2),
which may be another important factor in the efficacy of
delayed treatment. However, this was only demonstrated
in the animal model, so clinical trials will be needed to
verify this in human subjects in the future.
Conclusion
We have proven the efficacy of delayed treatment of
China-made Peramivir at enhancing survival rates and re-
ducing lung virus titers, and the maintenance of the drug
concentration in blood following virus infection. These
findings indicate the promising potential of China-made
Peramivir for the treatment of influenza virus infections
with delayed diagnosis, including avian influenza viruses,
aiding control of influenza epidemics in China.
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